Drug Trial Radar · NCT07861412
A Prospective Interventional Study of Intranasal Zavegepant for the Acute Treatment of Migraine
Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Sep 30, 2026
Primary completion
Dec 30, 2027
Study completion Mar 30, 2028
Sponsor
- Lead sponsor
- American Center for Psychiatry and NeurologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 6, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To evaluate the effectiveness of zavegepant in real-world settings for the acute treatment of migraine. Effectiveness will be evaluated based on the treatment of the first acute migraine attack with zavegepant, in order to capture clinically meaningful treatment response under real-world conditions while minimizing patient burden and missing data. Clinically meaningful treatment response is defined as: An improvement in a patient's condition that is large enough to be perceived as beneficial and to have a tangible impact on how the patient feels and functions. Secondary Objectives: To further evaluate the effectiveness of zavegepant for the acute treatment of migraine in real-world settings, including: * Pain freedom * Absence of the patient-identified most bothersome symptom (MBS) * Absence of individual migraine-associated symptoms (phonophobia, photophobia, and nausea) at 1 hour and 2 hours post dose, among participants with symptoms present at baseline * Sustained pain relief * Return to normal function * Rescue medication use Exploratory objectives include: * Evaluation of early treatment response at post-dose timepoints up to 60 minutes * Assessment of consistency of treatment effect across multiple migraine attacks * Time to meaningful pain relief as reported by the participant for the first treated attack Patient-Reported Outcomes: Patient-reported outcomes will be collected over a 3-month period to assess the longitudinal patient experience and sustained treatment impact in routine clinical practice.
Conditions
- Migraine
Interventions
Patient Headache DiaryOther
Patients will be asked to provide information on the first 2-3 headache attacks during the study
Patient Reported OutcomeOther
* Headache Impact Test (HIT-6) to assess the impact of headache on daily functioning and quality of life, collected at screening and V 4 * Migraine Disability Assessment (MIDAS) to evaluate migraine-related disability and functional impairment, collected at screening and V 4 * Patient Global Impression of Improvement (PGI-I) to assess the participants overall perception of treatment benefit, collected V 4 * Work Productivity and Activity Impairment (WPAI: Migraine 2.0) questionnaire to evaluate the effect of migraine on work productivity and daily activities. collected at screening and V 4 * The Patient Health Questionnaire-4 (PHQ-4) is used to assess the presence and severity of both depressive and anxiety symptoms, collected at screening and V 4 * Generalized Anxiety Disorder-7 (GAD-7) to evaluate the presence and severity of anxiety symptoms, collected at screening and V 4 has context menu
intranasal zavegepantDrug
This intervention is free of charge for the participants of this trial.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants reporting pain relief at 2 hours post-dose following the first use of zavegepant for an acute migraine attack.Time frame: From enrollment to end of treatment at month 4
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.